Alyeska details 2.5% BiomX (PHGE) stake in amended 13G filing

Rhea-AI Filing Summary

Alyeska Investment Group and related reporting persons filed an amended Schedule 13G showing beneficial ownership of 38,176 shares of BiomX Inc. common stock, representing 2.5% of the class. This amount includes 1 share of common stock and warrants to purchase 38,175 additional shares.

The ownership percentage is based on 1,526,640 BiomX common shares outstanding, after a 19:1 reverse stock split reported in a prior Form 8-K. The filers certify the position is held in the ordinary course of business and not for changing or influencing control of BiomX.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

BiomX Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

09090D301

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09090D301

1

Names of Reporting Persons

Alyeska Investment Group, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 38,176.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 38,176.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

38,176.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 09090D301

1

Names of Reporting Persons

Alyeska Fund GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 38,176.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 38,176.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

38,176.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 09090D301

1

Names of Reporting Persons

Anand Parekh

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 38,176.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 38,176.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

38,176.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BiomX Inc.
(b)	Address of issuer's principal executive offices: 22 Einstein St., Floor 4, Ness Ziona, Israel 7414003
Item 2.
(a)	Name of person filing: (i) Alyeska Investment Group, L.P. (ii) Alyeska Fund GP, LLC (iii) Anand Parekh
(b)	Address or principal business office or, if none, residence: (i) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (ii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601 (iii) 77 West Wacker Drive, 7th Floor, Chicago, IL 60601
(c)	Citizenship: (i) Alyeska Investment Group, L.P. - Delaware (ii) Alyeska Fund GP, LLC - Delaware (iii) Anand Parekh - United States of America
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 09090D301
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 38,176
(b)	Percent of class: 2.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 38,176
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 38,176
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Alyeska Investment Group, L.P.

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Alyeska Fund GP, LLC

Signature:	Jason Bragg
Name/Title:	Jason Bragg | Chief Financial Officer
Date:	02/17/2026

Anand Parekh

Signature:	Anand Parekh
Name/Title:	Anand Parekh | Self
Date:	02/17/2026

Exhibit Information

The reporting persons are the beneficial owners of 1 share of Common Stock of the Issuer and hold warrants to purchase 38,175 shares of the Issuer's Common Stock (the "Warrants"). The percentage calculation assumes that there are currently 1,526,640 outstanding Common Stock of the Issuer, after giving effect to the 19:1 reverse stock split, as reported on the issuer's Form 8-K filed with the Securities and Exchange Commission on November 17, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

FAQ

What stake in BiomX Inc. (PHGE) does Alyeska report in this 13G/A?

Alyeska and related reporting persons report beneficial ownership of 38,176 BiomX common shares, equal to about 2.5% of the class. This figure is based on 1,526,640 shares outstanding after a 19:1 reverse stock split disclosed in a prior Form 8-K.

How is the 2.5% BiomX (PHGE) ownership by Alyeska composed?

The reported 2.5% position consists of 1 BiomX common share plus warrants to purchase 38,175 additional common shares. All 38,176 shares are reported with shared voting and dispositive power among the reporting persons, with no sole voting or dispositive authority listed.

What share count did Alyeska use to calculate its BiomX (PHGE) ownership percentage?

The 2.5% ownership is calculated using 1,526,640 BiomX common shares outstanding. That share count reflects a 19:1 reverse stock split, as referenced from BiomX’s Form 8-K filed with the SEC on November 17, 2025, and underpins the percentage figure disclosed.

Do Alyeska and the other filers seek control of BiomX (PHGE) with this stake?

The reporting persons certify the BiomX securities were acquired and are held in the ordinary course of business. They state the holdings were not acquired and are not held to change or influence control of BiomX, except for limited activities related to certain nomination rules.

Who are the reporting persons in this BiomX (PHGE) Schedule 13G/A?

The filing lists three reporting persons: Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh. Each reports the same 38,176 BiomX shares with shared voting and dispositive power, and each indicates beneficial ownership of 2.5% of the common stock class.

What type of securities linked to BiomX (PHGE) does Alyeska hold?

The reporting persons beneficially own 1 share of BiomX common stock and hold warrants for 38,175 BiomX common shares. These warrants, together with the single share, make up the 38,176 shares reported as beneficially owned and used to calculate the 2.5% stake.